bluuebunny/crossref_metadata_2025_split huggingface dataset:
The Value of Community Technology Workers in LPG Adoption: A pilot in Shirati, Tanzania
Authors: Wiehl Annelise Marie , Sievers Sara , Kammen Daniel 
Published: September 2020

Abstract
Background: The issue of clean cooking lies at the nexus of environmental engineering, environmental health, pollution, energy access, gender and household dynamics, behavioral sciences and international development. In Tanzania, approximately 96% of the population relies on polluting or “unclean” fuels for cooking. Moving away from firewood and charcoal has proven challenging due to low adoption of clean stoves. Here we investigate the application of community health workers, an existing community engagement model for health systems, to clean cooking adoption. We implemented a pilot study with Community Technology Workers as a means to overcome maintenance, education, and behavioral barriers. We evaluated the training, work, and impact of a CTW on stove adoption on a sample of 30 households over a one-year period. Technically trained local CTWs educated thirty families on the Liquefied Petroleum Gas (LPG) stove and conducted weekly check-in surveys.Results: The results from the mixed methodology approach show that families initially have very high rates (100%) of adoption, but as the issues of poverty, other obligations, and sickness arise, roughly 70% of families present sustained, regular refilling of LPG cylinders.Conclusions: The findings imply the feasibility of this type of community infrastructure model to promote and facilitate adoption, but also supports the need to couple this local support with financial mechanisms (e.g. a savings bank). The support from these community trainers paired with these high rates of adoption have large implications for this model’s use in rural, poor areas to increase LPG use and adoption.
The Effects of Add-on Self-Care Therapy on Epidural Catheter Analgesia and Quality of Life in Patients after Surgical Stabilization of Multiple Rib Fractures
Authors: Wu Chunmei , Hong Yijin , Wu Biyu , Huang Biyan 
Published: September 2020

Abstract
Background: Epidural (EPI) catheter analgesia is frequently prescribed as a regional analgesic technique to patients with multiple rib fractures (MRF) following surgical stabilization of rib fractures (SSRF). We aimed to study the effect of add-on self-care therapy on recovery and quality of life (QoL) in patients on EPI analgesia after SSRF. Methods: A total of 267 patients with MRF and on EPI catheter analgesia post SSRF were recruited, and assigned to one of two groups in a random fashion: intervention group received education on self-care therapy, while the control group did not. Incentive spirometry (IS) volumes, Pain scores, oxygen saturation (SpO2), respiratory rate, hospital length of stay (LoS) and QoL were evaluated. Results: Compared to control group, the intervention group showed significantly improved pain scores, IS volume, respiratory rate and SpO2. Hospital LoS was shorter for the intervention group than control. Overall QoL assessments in the intervention group were also significantly better than control patients. Conclusion: Education on self-care therapy significantly benefits pain management, recovery and QoL for MRF patients on EPI catheter analgesia after SSRF operation.
Adult-onset Autoimmune Diabetes: Comparative Analysis of Classical and Latent Presentation
Authors: Fadiga Lúcia , Saraiva Joana , Catarino Diana , Frade João , Melo Miguel , Paiva Isabel 
Published: September 2020

Abstract
Introduction: Adult-onset autoimmune diabetes (AID) has two different phenotypes: classic type 1 diabetes mellitus (T1DM), with insulin requirement just after diagnosis, and latent autoimmune diabetes in adults (LADA). The purpose of this study is to characterize patients with AID followed on a tertiary centre, comparing classic T1DM and LADA.Methods: We collected data from patients with diabetes and positive islet autoantibodies, aged 30 years old and over at diagnosis. Patients who started insulin in the first 6 months were classified as T1DM and patients with no insulin requirements in the first 6 months were classified as LADA. Data regarding clinical presentation, autoantibodies, A1C and C-peptide at diagnosis, pharmacologic treatment and complications were analysed. Results: We included 92 patients, 46 with classic T1DM and 46 with LADA. The percentage of females was 50% in T1DM group and 52.1% in LADA group. The median age at diagnosis was 38 years (IQR – 15) for T1DM and 42 years (IQR – 15) for LADA (p=0.057). The median time between diagnosis of diabetes and diagnosis of autoimmune aetiology was 0 months in T1DM group and 60 months in LADA group (p<0.001). The mean BMI at diagnosis was 24.1Kg/m2 in T1DM group and 26.1Kg/m2 in LADA group (p=0.042). In T1DM group, 67.4% of the patients had more than one positive autoantibody, comparing to 41.3% of LADA patients (p=0.012). There was no statistical difference in what concerns to title of GAD autoantibodies, A1C and C-peptide at diagnosis of autoimmune aetiology. The presence of symptoms at diagnosis was associated with T1DM group (p<0.001). The median daily insulin dose was 40IU for T1DM (0.58IU/Kg) and 33.5IU for LADA (0.57IU/Kg), with no statistical difference. LADA patients were more often under non-insulin antidiabetic drugs (p=0.001). At 10 years follow up, 21.1% of T1DM patients and 63.3% of LADA patients had microvascular complications (p=0.004). Diabetic nephropathy was present in 23.5% of T1DM patients and 53.3% of LADA patients (p=0.047). At the last evaluation, 55.6% of T1DM and 82.6% of LADA patients had metabolic syndrome (p=0.005). Conclusion: Patients with classic T1DM presented more often with symptoms, lower BMI and higher number of autoantibodies, which may be related to a more aggressive autoimmune process. Patients with LADA developed more frequently microvascular complications for the same disease duration, namely diabetic nephropathy, and had more often metabolic syndrome.
Predictive and Prognostic Value of an microRNA Signature for Gastric Carcinoma Undergoing Adjuvant Chemotherapy
Authors: Cheng Xiaowei , Wei Hongkuang , Zhang Sheng , Zhang Fuzheng 
Published: September 2020

Abstract
PurposeGastric carcinoma (GC) is one of the most common cause of tumor-related death. Chemotherapy resistance usually occurs, leading to cancer relapse and poor survival of GC patients. To investigate the role of miRNAs in chemotherapy resistance for GC patients, we conducted an integrated analysis of miRNA expression and survival information using data obtained from the TCGA project. Materials and methodsGenome-wide screening of chemotherapy response-specific miRNAs was performed using Cox proportional hazards regression analyses for patients received chemotherapy or those had never received chemotherapy, respectively. CCK-8 assay was used for assessing cell viability. GSEA and single sample GSVA were performed for functional enrichment analysis. CIBERSORT cellular composition analysis was used to infer immune cell populations in GC tumors.ResultsA four-miRNA expression signature involving miR-130, -152, -199 and -200b was predicted as a specific indicator for GC chemoresistance (P = 0.00053; hazard ratio = 8.63), outperforming those clinicopathological factors. Functional experiments confirmed the roles of these signature miRNAs in regulation of chemotherapy response. Functional enrichment of these signature miRNAs and risk score revealed positive association with epithelial-mesenchymal transition (EMT), and negative association with cell cycle checkpoint and DNA damage response. Furthermore, the immune infiltration-miRNA functional network analysis revealed transformation from activated effector cells to resting immunosuppressive cells are preferred in GCs with adverse chemotherapy response.ConclusionsOur work identifies a four‑miRNA expression signature as a promising chemoresistance biomarker in gastric carcinoma, which provides novel insights into developing new strategies to overcome GC chemoresistance.
Identification and Validation of a Reliable Prognostic Eleven-Genes Signature for Hepatocellular Carcinoma
Authors: Li Yuliang , Liu Zhirui , Wang Qian 
Published: September 2020

Abstract
Background: Hepatocellular carcinoma (HCC) is a common malignant tumor with high mortality and mortality. Although advances in early diagnosis, disease management and treatment of HCC, the outcomes remain unsatisfactory. This study aimed to identify the reliable prognostic biomarkers based integrated bioinformatics analysis to predict and improve the survival of HCC patients. Methods: The gene expression or transcriptome profiles and survival of HCC were acquired from the Gene Expression Omnibus database (GEO) and the Cancer Genome Atlas (TCGA) database. Differentially expressed genes (DEGs) were screened out by the limma or edgeR package in the R software. Univariate, LASSO and multivariate Cox regression analyses were conducted to explore survival-related signature. Subsequently, a prognostic model and nomogram composed of prognostic signature were constructed for assessing overall survival (OS). Kaplan-Meier analysis, receiver operating characteristic (ROC) curve and stratified analysis were performed to confirm the prognostic performance of the prognostic model.Results: Compared with nontumor samples, 451 reliable DEGs were identified using the robust rank aggregation and overlap validation. Eleven survival-related DEGs were selected for the construction of a risk evaluation model, which could efficiently distinguish high-risk patients from low-risk patients and even be feasible in the subgroups of stages and age. Further analyses suggested the positive and independent prognostic performance of the model compared to other clinical characteristics (P< 0.05, ROC > 0.7). Finally, a prognostic nomogram composed of the model was constructed for assessing the overall survival, and Harrell’s concordance index and calibration curves demonstrated its efficient predictive performance. Conclusion: The predictive model and nomogram will contribute directly to further clinical applications in the individualized survival prediction, the improvement of treatment strategies and more accurate management for patients with HCC.
Aberrant SLC6A14 Expression Promotes Proliferation and Metastasis of Colorectal Cancer Via Enhancing the JAK2/STAT3 Pathway
Authors: Mao Hongli , Sheng Jinxiu , Jia Jinlin , Wang Chang , Zhang Shanfeng , Xing Yurong , He Fucheng 
Published: September 2020

Abstract
Background: Solute carrier family 6 member 14 (SLC6A14) is a high-capacity amino acid transporter in mammalian cells. It has gained increasing attention for its potential involvement in the progression and metabolic reprogramming of various malignant tumors. However, the role of SLC6A14 in colorectal cancer (CRC) remains unclear. Methods: Real-time polymerase chain reaction (qRT-PCR), immunoblotting and immunohistochemistry were carried out to detect the expression level of SLC6A14 in human CRC tissues and CRC-derived cell lines. HCT-116 and Caco-2 cell lines were selected to conduct the in vitro functional studies. Cell Counting Kit-8 (CCK-8), colony formation, flow cytometry, cell migration and invasion assays were performed to investigate the role of SLC6A14 in CRC cells. Besides, Azoxymethane/Dextran Sulfate Sodium Salt (AOM/DSS)-induced CRC and tumor xenograft models were constructed to explore the effects of SLC6A14 blockade or overexpression on tumor progression in vivo. Results: SLC6A14 was substantially increased in human CRC samples and higher levels of SLC6A14 was correlated with advanced tumor stage, lymph node metastasis and dismal survival of CRC patients. SLC6A14 markedly promoted cell growth, inhibited cell apoptosis, exacerbated migration and invasion of CRC cells in vitro. Mechanistically, SLC6A14 aggravated these malignant phenotypes through activating JAK2/STAT3 signaling pathway, and inhibiting JAK2/STAT3 signaling with specific inhibitors could reverse SLC6A14-mediated tumorigenic effects. Besides, two different animal studies verified the tumor-promoting effect of SLC6A14 in CRC. Conclusion: Our data illustrated the crucial function that SLC6A14 played in the promotion of CRC, suggesting SLC6A14/JAK2/STAT3 axis may serve as novel therapeutic targets for patients with CRC.
Lupus Anticoagulant Hypoprothrombinemia Syndrome Associated with Bilateral Adrenal Hemorrhage in a Child: Early Diagnosis and Intervention
Authors: Sakamoto Atsushi , Ogura Masao , Hattori Atsushi , Tada Kinji , Horikawa Reiko , Nakadate Hisaya , Matsumoto Kimikazu , Nogami Keiji , Ieko Masahiro , Ishiguro Akira 
Published: September 2020

Abstract
Background: Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is characterized by bleeding and thrombosis in patients, usually associated with autoimmunity or infections. Pediatric LAHPS exhibits various degrees of bleeding, ranging from mild to severe; however, adrenal hemorrhage due to LAHPS and its long-term clinical course have not been sufficiently described. Case presentation: A 9‐year‐old boy presented with prolonged abdominal pain and abnormal coagulation screening tests. The laboratory tests showed prolonged activated partial thromboplastin time and subsequently revealed the presence of lupus anticoagulant, anti-nuclear antibodies, and hypoprothrombinemia, leading to diagnosis of LAHPS. An enhanced computed tomogram demonstrated nodular lesions in the adrenal glands bilaterally, suggestive of adrenal hemorrhage. Laboratory and clinical manifestations exhibited life-threatening adrenal insufficiency that required hydrocortisone administration. The patient developed systemic lupus erythematosus, diagnosed 12 months later. Conclusions: The patient with LAHPS developed rare adrenal failure due to adrenal hemorrhage, a life-threatening event that should be recognized and treated early. In our case, renal dysfunction was also observed when systemic lupus erythematosus was diagnosed one year after LAHPS. Our case emphasizes that early recognition of adrenal failure and careful observation for patients with autoantibodies are required.
Analysis of Drug Resistance in Helicobacter Pylori by Complete Genome Sequencing in Bama County, Guangxi, China
Authors: huang yanqiang , Li Xiao-Hua , Huang Yong-Yi , Luo Xian-ke , Qin Yan-Chun , Dai Yuan-Yuan , Qin Chun , Li Ru-Jia , Chen Hao 
Published: September 2020

Abstract
Background: The resistance rate of clinical Helicobacter pylori (Hp) isolates has increased, however, the mechanism of drug resistance is unclear. In this study, we isolated drug-resistant Hp strains isolated from different areas and different populations of China for genomic analysis.Objectives: The aim of this study was to investigate drug resistance in Hp from Bama County, Guangxi, China.Methods: Minimal inhibitory concentrations (MICs) of clarithromycin, metronidazole and levofloxacin were determined and complete genome sequencing was performed with annotation. The presence of hp1181 and hp1184 genes was detected by RT-PCR. The relationships between hp1181, hp1184 and clarithromycin resistance were confirmed by gene mutation and drug-resistant strains. Results: Three drug-resistant Hp strains were isolated from patients with gastritis in Bama County. The strains showed a high degree of homology with hp26695 through complete genome detection and identification. Differences in genome sequences, gene quantity and gene characteristics were detected amongst the three strains. Prediction and analysis of the function on drug-resistant genes indicated that the RNA expression of hp1181 and hp1184 increased in the three strains that were the same in the artificially induced clarithromycin-resistant bacteria. After gene knockout, the drug sensitivity of the strains increased significantly.Conclusions: The expressions of the genes hp1184 and hp1181 were associated with clarithromycin resistance in the Hp from Bama, Guangxi.
Computational screening of phytocompounds from Moringa oleifera leaf as potential inhibitors of SARS-CoV-2 Mpro
Authors: D Athira Nair , J James T 
Published: September 2020

Abstract
Background: Coronavirus Disease (COVID-19), caused by novel SARS CoV-2 is rapidly spreading all over the World creating a global public health emergency at unprecedented levels. Till today, no effective treatments or vaccines against this global pandemic is reported and hence to identify lead compounds having potential action in controlling the spread the pandemic is a global concern. This study aimed at in silico screening of phytocompounds from M.oleiera leaf against novel SARS CoV-2 main protease (Mpro) through molecular docking. M.oleiera is an Indian medicinal plant as well as a vegetable, all parts of the plant is medicinally useful and is being used in many of the traditional and Ayurvedic medicinal preparations. Result: When the 19 compounds identified from M.oleifera leaf methanolic extract by Liquid Chromatography Mass Spectrometry (LCMS/MS) analysis and 5 FDA approved anti-viral drugs were screened in silico with SARS CoV-2 main protease (Mpro), the following compounds showed top interaction; apigenin-7-O-rutinoside (-8.8 kcal/mol), Mudanpioside (-8.3 kcal/mol), isoquercetin (-8 kcal/mol), isoquercitrin (-8 kcal/mol), quercetin (-7.8 kcal/mol) and dihydroquercetin (-7.8 kcal/mol). Anti-viral drugs: Raltegravir (-7.2 kcal/mol), Lopinavir-Ritonavir (-7.7 kcal/mol), maraviroc (-8.2 kcal/mol), Nelfinavir (-8.3 kcal/mol) and Tipranavir (-9.2 kcal/mol) also showed active interaction with Mpro. Preliminary phytochemical screening of methanol extract showed the presence of flavonoids, cardiac glycosides, phenols, coumarins, saponins, steroids and phytosteroids. In vitro antioxidant activity of methanolic extract of M.oleifera also showed greater activity, which would ameliorate the post-COVID secondary infection. Conclusion: Hence these compounds from M.oleifera, which are our diet based components, which can interact with the Mpro and curtail COVID-19 virus multiplication in the host cell.
­­­Multi-locus phylogenies reveal three new truffle-like taxa and the traces of interspecific hybridization in Octaviania (Boletales)
Authors: Orihara Takamichi , Healy Rosanne , Corrales Adriana , Smith Matthew E. 
Published: September 2020

Abstract
Among many convergently evolved sequestrate fungal genera in Boletaceae (Boletales, Basidiomycota), the genus Octaviania is the most diverse. We recently collected many specimens of Octaviania subgenus Octaviania, including several undescribed taxa, from Japan and the Americas. Here we describe two new species in subgenus Octaviania, O. tenuipes and O. tomentosa, from temperate to subtropical evergreen Fagaceae forests in Japan based on morphological observation and robust multi-locus phylogenetic analyses (nrDNA ITS and partial large subunit [LSU], translation elongation factor 1-α gene [TEF1] and the largest subunit of RNA polymerase II gene [RPB1]). Based on specimens from the Americas as well as studies of the holotype, we also taxonomically re-evaluate the taxon O. asterosperma var. potteri. Our analysis suggests that O. asterosperma var. potteri is a distinct taxon within the subgenus Octaviania so we recognize this as O. potteri. We unexpectedly collected O. potteri specimens from geographically widespread sites in the USA, Japan and Colombia. This is the first verified report of Octaviania from the South American continent. Our molecular analyses also revealed that the RPB1 sequence of one O. tenuipes specimen was identical to that of a closely related species, O. japonimontana, and that one O. potteri specimen from Minnesota had an RPB1 sequence of an unknown species of O. subg. Octaviania. Additionally, one O. japonimontana specimen had an unusually divergent TEF1 sequence. Gene-tree comparison and phylogenetic network analysis of the multi-locus dataset suggest that these heterogenous sequences are most likely the result of previous inter- and intra-specific hybridization. We hypothesize that frequent hybridization events in Octaviania may have promoted the high genetic and species diversity within the genus.
Rare SARS-CoV-2 antibody development in cancer patients
Authors: hempel louisa , Molnar Jakob , Robert Sebastian , veloso julia , Trepotec Zeljka , Englisch Sofie , Weinzierl Philip , Milani Valeria , Schweneker Katrin , Fleischmann Bastian , Scheiber Josef , Gandorfer Beate , Kleespies Axel , Kaminski Wolfgang , Hempel Dirk , Riedman Kristina , Piehler Armin 
Published: September 2020

Abstract
SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now, it has been assumed that patients who were infected with SARS-CoV-2 develop antibodies as it is the case with other coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the antibody development of 77 oncology patients 26 days after positive RT-qPCR testing for SARS-CoV-2. RT-qPCR and anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used, respectively, according to the manufacturers’ specifications.Surprisingly, in only 6 of 77 individuals with a confirmed history of COVID-19 antibody development was detected. Despite of multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent tests. These results undermine the previous hypothesis that SARS-CoV-2 infections are regularly associated with antibody development and cast doubt on the provided immunity to COVID-19. Understanding the adaptive and humoral response to SARS-CoV-2 will play a key-roll in vaccine development and gaining further knowledge on the pathogenesis.
Iguratimod Inhibits Renal Interstitial Fibrosis in Lupus Nephritis
Authors: Xue Leixi , Xu Jiajun , Lu Wentian , Wang Qing , Weng Chenghua , Zhang Yi , Wen Jian , Fu Jinxiang , Liu Zhichun 
Published: September 2020

Abstract
Background: Renal interstitial fibrosis (RIF) is one of the main poor prognostic factors of lupus nephritis (LN). Here, we tested whether iguratimod could inhibit RIF in LN. Methods: MRL/lpr mice, an animal model of lupus, were treated with iguratimod or vehicle solution. Pathological changes of kidney was evaluated blindly by the same pathologist. Renal type I collagen (COL-I), IgG, E-cadherin, fibroblast-specific protein 1 (FSP-1) were detected by immunofluorescence, immunohistochemical staining or quantitative real-time PCR. After treated with transforming growth factor β1 (TGF-β1) and iguratimod, E-cadherin, fibronectin, Smad2/3, p38 MAPK, p-Smad2/3 and p-p38 MAPK in HK2 cells were measured by western blotting, quantitative real-time PCR or immunofluorescence. Results: In MRL/lpr mice, iguratimod eased the renal interstitial deposition of collagen fibers, further confirmed by decreased expression of COL-I after iguratimod treatment. Moreover, upstream pathological processes of RIF, including IgG deposition along the tubular basement membrane, infiltration of inflammatory cells into renal interstitium and tubular injury, were also prevented effectively by iguratimod treatment. Furthermore, iguratimod suppressed the expression of FSP-1 and raised the expression of E-cadherin in renal tubular epithelial cells, suggesting that iguratimod reversed the process of tubular epithelial-to-mesenchymal transition (EMT). In HK2 cells induced by TGF-β1, co-treatment with iguratimod not only reversed cellular morphologic change, but also prevented down-regulation of E-cadherin and up-regulation of fibronectin. Finally, iguratimod blocked TGF-β1-induced phosphorylation of Smad2/3 and p38 MAPK in HK2 cells. Conclusions: Our results suggest that iguratimod shows an inhibitory effect on the progress of RIF in vivo and in vitro, so iguratimod may be a potential drug for the treatment of RIF in LN.